Multi-agent oral mucositis composition for cancer therapy support
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for oral inflammation and pain associated with cancer chemotherapy and radiotherapy are inadequate, leading to significant distress and complications that can delay or limit the effectiveness of cancer therapy, and there is a need for new compositions to prevent or delay the onset of these conditions.
Innovation Solution
The development of pharmaceutical compositions comprising compounds such as clonidine, lidocaine, benzocaine, prilocaine, and bupivacaine in the form of hydrates, solvates, enantiomers, or stereoisomers, combined with pharmaceutically acceptable carriers, for systemic or topical administration, to treat and prevent inflammation and pain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If multiple interventional approaches are used to decrease emotional and physical distress from acute oral pain and mucositis, then patient comfort and treatment compliance improve, but treatment complexity and number of interventions increase
Solution Approach 1:
The patent combines multiple therapeutic agents (local anesthetics such as lidocaine, benzocaine, prilocaine, bupivacaine, and clonidine) into a single pharmaceutical composition that can be administered as one intervention rather than multiple separate treatments, thereby improving patient comfort and compliance while reducing treatment complexity
Solution Approach 2:
The pharmaceutical composition is designed to provide multiple therapeutic effects simultaneously - analgesia, anti-inflammatory action, and mucosal protection - through a single multi-component formulation, allowing one intervention to address multiple symptoms of oral mucositis and pain
2Reliability
If rapid mitosis in mucosal tissue is targeted to prevent injury from chemotherapy and radiation, then mucosal integrity is protected, but the effectiveness of cancer therapy may be reduced
Solution Approach 1:
The patent applies local anesthetics and protective agents directly to the oral mucosa through topical administration or mouthwash formulations, providing localized protection to the mucosal tissue without affecting the systemic effectiveness of chemotherapy and radiation therapy against cancer cells
Solution Approach 2:
The pharmaceutical composition acts as an intermediary protective layer on the oral mucosa, shielding the tissue from the damaging effects of chemotherapy and radiation while allowing these cancer treatments to continue their systemic action against malignant cells
Data Source
AI summary
The invention relates to the compounds of formula I, formula II, formula III, formula IV and formula V or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV or formula V and methods for the treatment of inflammation and pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of pain, oral mucosal inflammatory or oral infectious diseases.